ClinVar Miner

Submissions for variant NM_000179.3(MSH6):c.4001+2TAAC[2]

dbSNP: rs267608132
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 29
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
International Society for Gastrointestinal Hereditary Tumours (InSiGHT) RCV000074968 SCV000108184 likely benign Lynch syndrome 2019-06-21 reviewed by expert panel curation No effect on splicing in minigene & RT-PCR assay
Ambry Genetics RCV000160732 SCV000187066 likely benign Hereditary cancer-predisposing syndrome 2018-01-04 criteria provided, single submitter clinical testing This alteration is classified as likely benign based on a combination of the following: population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity.
GeneDx RCV000160732 SCV000211368 benign Hereditary cancer-predisposing syndrome 2014-08-19 criteria provided, single submitter clinical testing The variant is found in HEREDICANCER,COLO-HEREDIC panel(s).
Invitae RCV001079571 SCV000262471 benign Hereditary nonpolyposis colorectal neoplasms 2024-02-01 criteria provided, single submitter clinical testing
Eurofins Ntd Llc (ga) RCV000202155 SCV000339455 benign not specified 2016-02-04 criteria provided, single submitter clinical testing
Counsyl RCV000412187 SCV000489228 likely benign Lynch syndrome 5 2016-09-06 criteria provided, single submitter clinical testing
Genetic Services Laboratory, University of Chicago RCV000202155 SCV000595844 likely benign not specified 2019-03-04 criteria provided, single submitter clinical testing
Quest Diagnostics Nichols Institute San Juan Capistrano RCV000202155 SCV000601598 likely benign not specified 2016-12-20 criteria provided, single submitter clinical testing
Color Diagnostics, LLC DBA Color Health RCV000160732 SCV000690428 likely benign Hereditary cancer-predisposing syndrome 2015-02-13 criteria provided, single submitter clinical testing
PreventionGenetics, part of Exact Sciences RCV000656542 SCV000805901 likely benign not provided 2017-08-11 criteria provided, single submitter clinical testing
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000202155 SCV000919767 benign not specified 2018-04-30 criteria provided, single submitter clinical testing Variant summary: MSH6 c.4001+12_4001+15delACTA variant results in 4 intronic nucleotides deletion, with 5/5 computational tools predicting no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. The variant allele was found at a frequency of 0.0012 in 270798 control chromosomes (gnomAD). The observed variant frequency is approximately 8.7 fold of the estimated maximal expected allele frequency for a pathogenic variant in MSH6 causing Lynch Syndrome phenotype (0.00014), strongly suggesting that the variant is benign. The variant, c.4001+12_4001+15delACTA, has been reported in the literature in individuals affected with Lynch Syndrome but also in unaffected controls and was classified as a polymorphism (Peterlongo_2003, Naruse_2009). In addition, the variant was detected in a patient with the pathogenic MSH2 variant c.211+1G>C that was shown to cause aberrant splicing (Naruse_2009). Since the penetrance of Lynch Syndrome (0.67) due to this variant appears to be lower than expected (0.8), no conclusions can be drawn from these data. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation and the majority classified the variant as likely benign/benign. Based on the evidence outlined above, the variant was classified as benign.
Mendelics RCV000412187 SCV001135859 likely benign Lynch syndrome 5 2019-05-28 criteria provided, single submitter clinical testing
Cancer Genomics Group, Japanese Foundation For Cancer Research RCV001030564 SCV001193654 uncertain significance Hereditary breast ovarian cancer syndrome 2019-05-01 criteria provided, single submitter research
CeGaT Center for Human Genetics Tuebingen RCV000656542 SCV001501274 likely benign not provided 2024-04-01 criteria provided, single submitter clinical testing MSH6: BS1
Institute for Clinical Genetics, University Hospital TU Dresden, University Hospital TU Dresden RCV000656542 SCV002010080 likely benign not provided 2021-11-03 criteria provided, single submitter clinical testing
CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario RCV001798255 SCV002042056 likely benign Breast and/or ovarian cancer 2023-04-05 criteria provided, single submitter clinical testing
Center for Genomic Medicine, Rigshospitalet, Copenhagen University Hospital RCV000202155 SCV002552375 likely benign not specified 2023-08-15 criteria provided, single submitter clinical testing
Fulgent Genetics, Fulgent Genetics RCV002477213 SCV002803142 likely benign Endometrial carcinoma; Lynch syndrome 5; Mismatch repair cancer syndrome 3 2021-07-28 criteria provided, single submitter clinical testing
Institute for Biomarker Research, Medical Diagnostic Laboratories, L.L.C. RCV000160732 SCV004228069 benign Hereditary cancer-predisposing syndrome 2024-01-04 criteria provided, single submitter clinical testing
ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories RCV000656542 SCV004563327 likely benign not provided 2023-01-06 criteria provided, single submitter clinical testing
Mayo Clinic Laboratories, Mayo Clinic RCV000656542 SCV000257294 likely benign not provided 2017-11-10 no assertion criteria provided clinical testing
Genome Diagnostics Laboratory, Amsterdam University Medical Center RCV000412187 SCV000745655 likely benign Lynch syndrome 5 2016-04-29 no assertion criteria provided clinical testing
True Health Diagnostics RCV000160732 SCV000788055 likely benign Hereditary cancer-predisposing syndrome 2017-08-11 no assertion criteria provided clinical testing
Ding PR Lab, Sun Yat-sen University Cancer Center RCV001093682 SCV001250863 uncertain significance Lynch syndrome 1 no assertion criteria provided clinical testing
Department of Pathology and Laboratory Medicine, Sinai Health System RCV001355407 SCV001550287 likely benign Malignant tumor of breast no assertion criteria provided clinical testing The MSH6 c.4001+12_4001+15dupACTA variant was identified in 1 of 1500 proband chromosomes (frequency: 0.0007) from individuals or families with CRC and was identified as a non-pathogenic variant (Woods 2010). The variant was also identified in dbSNP (ID: rs587782538) as “With other allele”, ClinVar (4x, as benign by GeneDx, as likely benign by Ambry, Invitae and Counsyl), Clinvitae (3x, as likely benign), and the Insight Colon Cancer Gene Variant Database (3x, as uncertain). The variant was not identified in COGR, MutDB, UMD-LSDB, Zhejiang Colon Cancer Database, or the Mismatch Repair Genes Variant Database. The variant was identified in control databases in 75 of 270198 chromosomes at a frequency of 0.0003 in the following populations: African in 17 of 23654 chromosomes (freq. 0.0007), Latino in 13 of 34140 chromosomes (freq. 0.0004), European in 35 of 123578 chromosomes (freq. 0.0003), East Asian in 5 of 1860 chromosomes (freq. 0.0003), and other in 1 of 6346 chromosomes (freq. 0.0002), Ashkenazi Jewish in 1 of 10042 chromosomes (freq. 0.0001), South Asian in 3 of 30528 chromosomes (freq. 0.0001), increasing the likelihood that this may be a low frequency benign variant in certain populations of origin (Genome Aggregation Consortium Feb 27, 2017). The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer, HumanSpliceFinder) do not predict a difference in splicing. A co-occurring pathogenic BRCA1 variant (c.709G>T, p.Glu237X) was identified in 1 individual with breast cancer in our laboratory, increasing the likelihood that c.4001+12_4001+15dupACTA variant does not have clinical significance In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time although we would lean towards a more benign role for this variant. This variant is classified as likely benign.
Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen RCV000656542 SCV001744796 likely benign not provided no assertion criteria provided clinical testing
Genome Diagnostics Laboratory, Amsterdam University Medical Center RCV000656542 SCV001808343 likely benign not provided no assertion criteria provided clinical testing
Clinical Genetics, Academic Medical Center RCV000202155 SCV001921925 benign not specified no assertion criteria provided clinical testing
Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center RCV000656542 SCV001972565 likely benign not provided no assertion criteria provided clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.